DOCSLIB.ORG

Pharmaceutical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical SafeSafe HarborHarbor StatementStatement ThisThis presspress releaserelease containscontains "forward"forward-looking-looking statements"statements" asas defineddefined inin thethe PrivatePrivate SecuritiesSecurities LitigationLitigation ReformReform ActAct ofof 1995.1995. TheseThese statementsstatements areare basedbased onon currentcurrent expectationsexpectations ofof futurefuture events.events. IfIf underlyingunderlying assumptionsassumptions proveprove inaccurateinaccurate oror unknownunknown risksrisks oror uncertaintiesuncertainties materialize,materialize, actualactual resultsresults couldcould varyvary materiallymaterially fromfrom JohnsonJohnson && Johnson'sJohnson's expectationsexpectations andand projections.projections. RisksRisks andand uncertaintiesuncertainties includeinclude generalgeneral industryindustry conditionsconditions andand competition;competition; economiceconomic conditions,conditions, suchsuch asas interestinterest raterate andand currencycurrency exchangeexchange raterate fluctuations;fluctuations; technologicaltechnological advancesadvances andand patentspatents attainedattained byby competitors;competitors; challengeschallenges inherentinherent inin newnew productproduct dedevelopment,velopment, includingincluding obtainingobtaining regulatoryregulatory approvals;approvals; domesticdomestic andand foreignforeign healthhealth carecare reformsreforms andand governmentalgovernmental lawslaws andand regulations;regulations; andand trendstrends towardtoward healthhealth carecare costcost containment.containment. AA furtherfurther listlist andand descriptiondescription ofof thesethese risks,risks, uncertaintiesuncertainties andand otherother factorsfactors cancan bebe foundfound inin ExhibitExhibit 9999 ofof thethe Company'sCompany's AnnualAnnual ReportReport onon FormForm 10-K10-K forfor thethe fiscalfiscal yearyear endedended DecemberDecember 30,30, 2007.2007. CopiesCopies ofof thisthis FormForm 10-K,10-K, asas wellwell asas subsequentsubsequent filings,filings, areare availableavailable ononlineline atat www.sec.gov,www.sec.gov, www.jnj.comwww.jnj.com oror onon requestrequest fromfrom JohnsonJohnson && Johnson.Johnson. JohnsonJohnson && JohnsonJohnson doesdoes notnot undertakeundertake toto updateupdate anyany forward-lookingforward-looking statementsstatements asas aa resultresult ofof newnew informationinformation oror futurefuture eventsevents oror developments.developments. ContentContent OverviewOverview •• OperatingOperating ModelModel •• HistoricalHistorical PerformancePerformance •• SegmentSegment OverviewOverview •• SecondSecond QuarterQuarter 20082008 ResultsResults ••Summar Summaryy STRATEGICSTRATEGIC PRINCIPLESPRINCIPLES OperatingOperating ModelModel •• BroadlyBroadly BasedBased inin HumanHuman HealthHealth CareCare •• ManagedManaged forfor thethe LongLong TermTerm •• DecentralizedDecentralized ManagementManagement ApproachApproach •• PeoplePeople andand ValuesValues BroadlyBroadly BasedBased-- World’sWorld’s MostMost ComprehensiveComprehensive HealthHealth CareCare CompanyCompany •• 20072007 SalesSales ofof $61.1$61.1 BillionBillion •• OverOver 250250 operatingoperating companiescompanies worldwideworldwide •• LeadershipLeadership positionspositions inin ethicalethical andand OTCOTC pharmaceuticals,pharmaceuticals, medical/surgicalmedical/surgical products,products, diagnosticsdiagnostics andand aa varietyvariety ofof consumerconsumer productsproducts BroadlyBroadly BasedBased –– AA StrategicStrategic AdvantageAdvantage 20072007 SegmentSegment OperatingOperating Profit*Profit* $15.9B $14.6B $6.0 % to Sales $5.7 2006 25.7% 2007 26.0% $7.6 $6.9 $2.0 $2.3 2006 2007 Consumer Pharm MD&D *Proforma including net impact of PCH; Refer to 3.2.07 8K filing for 2006 PCH impact to operating profit; Excludes IPR&D and other special items BroadlyBroadly BasedBased –– AA StrategicStrategic AdvantageAdvantage •• RapidlyRapidly capitalizecapitalize onon attractiveattractive opportunitiesopportunities •• KnowledgeKnowledge andand capabilitycapability transfertransfer •• DevelopmentDevelopment ofof convergingconverging technologiestechnologies •• AcceleratingAccelerating growthgrowth throughthrough geographicgeographic breadthbreadth •• LeveragingLeveraging scalescale OperatingOperating ModelModel •• BroadlyBroadly BasedBased inin HumanHuman HealthHealth CareCare •• ManagedManaged forfor thethe LongLong TermTerm •• DecentralizedDecentralized ManagementManagement ApproachApproach •• PeoplePeople andand ValuesValues LeadershipLeadership inin MajorMajor MarketsMarkets JohnsonJohnson && JohnsonJohnson #1#1 oror #2*#2* Anti-AnemiaAnti-Anemia Lo-CalLo-Cal SweetenersSweeteners AntipsychoticsAntipsychotics BloodBlood GlucoseGlucose MonitoringMonitoring Anti-TNFAnti-TNF BloodBlood ScreeningScreening && TypingTyping HormonalHormonal ContraceptivesContraceptives ElectrophysiologyElectrophysiology diagnosticsdiagnostics andand QuinoloneQuinolone Anti-InfectiveAnti-Infective catheterscatheters CoronaryCoronary StentsStents DisposableDisposable ContactContact LensesLenses MinimallyMinimally InvasiveInvasive SurgerySurgery OTCOTC PharmaceuticalsPharmaceuticals OrthopaedicsOrthopaedics SanitarySanitary ProtectionProtection SuturesSutures WoundWound CareCare BabyBaby && KidsKids CareCare *As of Dec 2007 GrowthGrowth StrategiesStrategies •• OrganicOrganic growthgrowth –– StrongStrong internalinternal R&DR&D capabilitycapability –– NurtureNurture newnew businesses;businesses; PrunePrune wherewhere appropriateappropriate •• StrategicStrategic partneringpartnering andand licensinglicensing •• SelectiveSelective acquisitionsacquisitions –– EnhanceEnhance existingexisting businessbusiness –– NewNew platformplatform forfor growthgrowth 19971997––20072007 TotalTotal ResearchResearch ExpenseExpense $U.S.$U.S. BillionsBillions $7.7 $2.4 1997 2007 10.6% Percent to Sales 12.6% The company has adopted SFAS No. 123(R) Shared Based Payment, applying the modified retrospective transition method. 1997-2005 reported financial statements have been restated accordingly. PartnerPartner ofof ChoiceChoice •• OverOver 100100 newnew thirdthird partyparty relationshipsrelationships annuallyannually •• InIn househouse ventureventure capitalcapital (JJDC)(JJDC) –– OverOver $475$475 millionmillion investedinvested asas ofof 20072007 inin aa broadbroad arrayarray ofof companiescompanies •• FocusFocus onon earlyearly stagestage productproduct developmentdevelopment MergersMergers && AcquisitionsAcquisitions –– RecentRecent ExamplesExamples StrategicStrategic movesmoves toto enhanceenhance ourour growthgrowth raterate andand createcreate long-termlong-term valuevalue forfor ourour shareholdersshareholders TypicallyTypically modestmodest inin size:size: overover 6060 inin thethe lastlast decadedecade •• ÅÅmicmic (6/08)(6/08) -- aa privatelyprivately heldheld SwedishSwedish developerdeveloper ofof inin vitrovitro diagnosticdiagnostic (IVD)(IVD) technologiestechnologies forfor useuse inin Point-of-CarePoint-of-Care (POC)(POC) andand near-patientnear-patient settingssettings •• Disc-O-TechDisc-O-Tech MedicalMedical Technologies,Technologies, Ltd.Ltd. (12/07)(12/07) -- AcquisitionAcquisition ofof certaincertain assets,assets, includingincluding intellectualintellectual propertyproperty rights,rights, relatedrelated toto thethe treatmenttreatment ofof vertebralvertebral compressioncompression fracturesfractures fromfrom Disco-o-TechDisco-o-Tech MedicalMedical Technologies,Technologies, aa privatelyprivately heldheld company,company, andand itsits subsidiarysubsidiary •• EnsureEnsure Medical,Medical, Inc.Inc. (7/06)(7/06) -- AcquisitionAcquisition ofof EnsureEnsure Medical,Medical, aa privatelyprivately heldheld companycompany willwill provideprovide CordisCordis withwith aa developmentdevelopment stagestage femoralfemoral arteryartery closureclosure devicedevice (ACD)(ACD) andand relatedrelated IPIP andand know-howknow-how •• ColBarColBar LifeScienceLifeScience Ltd.Ltd. (7/06)(7/06) -- AcquisitionAcquisition ofof ColBarColBar LifeScience,LifeScience, anan IsraeliIsraeli ventured-backed,ventured-backed, privatelyprivately heldheld medicalmedical devicedevice companycompany withwith expertiseexpertise inin collagen-basedcollagen-based productsproducts MergersMergers && AcquisitionsAcquisitions –– RecentRecent ExamplesExamples •• VascularVascular ControlControl SystemsSystems (5/06)(5/06) -- AcquiredAcquired aa ventureventure fundedfunded privatelyprivately heldheld companycompany thatthat developeddeveloped technologytechnology thatthat willwill bebe usedused forfor thethe treatmenttreatment ofof fibroidsfibroids andand dysfunctionaldysfunctional uterineuterine bleedingbleeding •• GroupeGroupe VendomeVendome SASA (5/06)(5/06) -- JohnsonJohnson && JohnsonJohnson ConsumerConsumer FranceFrance SASSAS acquiredacquired GroupeGroupe Vendome,Vendome, aa privatelprivatelyy heldheld FrenchFrench marketermarketer ofof adultadult andand babybaby skinskin carecare productsproducts •• FutureFuture MedicalMedical SystemsSystems GroupGroup NVNV (FMS)(FMS) (3/06)(3/06) -- TheThe acquisitionacquisition ofof FMS,FMS, willwill allowallow DePuyDePuy MitekMitek toto enteenterr thethe fluidfluid managementmanagement andand shavershaver marketsmarkets andand increaseincrease DePuyDePuy Mitek’sMitek’s proproductduct offeringsofferings inin thethe arthroscopicarthroscopic surgicalsurgical marketmarket •• AnimasAnimas CorporationCorporation (2/06)(2/06) -- AcquisitionAcquisition ofof AnimasAnimas Corporation,Corporation, anan insulininsulin deliverydelivery company,company, affordsaffords
Load more

Recommended publications
  • Learner Notification International Society for Heart & Lung
    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Diabetes Close up December Supplement, 2005, No. 53 J&J To
    Diabetes Close Up December supplement, 2005, No. 53 J&J To Buy Animas in Sublime Strategic Play T h e S h o r t e r V e r s i o n From the Editor: J&J’s LifeScan announced December 16 that it intends to buy Animas Corporation for $518 million in cash, or $24.50/share, a 35% premium over Animas’ closing price the 15th. We think this acquisition makes very good strategic sense – essentially, it’s the #1 glucose monitoring company buying the #2 pump player. In many respects, this was a classic J&J deal – Animas is newly profitable this year, the deal is immediately accretive, and it offers J&J an excellent leg up as it enters the pump market. Too, J&J had owned ~10% of Animas for some time. Now, while Animas is #2, it is still far behind leader Medtronic MiniMed, whose new(ish) leader, successful cardiac surgery veteran Bob Guezuraga has really impressed the diabetes community. Smart, ambitious, and seemingly hyper-focused, he appears very serious about taking the business to the next level and leaving success in diabetes as his legacy. What could be better for patients than significant focus industry-wide on better physiologic delivery? As competition heightens, we expect innovation to move faster – all good, from a patient perspective. Details on the acquisition are below – what J&J gets, what Animas gets, and what’s next. What a way to end what’s been a very dynamic year in diabetes … --Kelly L. Close DCU #53, December supplement 2005, J&J Buys Animas in Sublimely Strategic Deal.
    [Show full text]
  • [J-52A-2014] in the Supreme Court of Pennsylvania Middle District
    [J-52A-2014] IN THE SUPREME COURT OF PENNSYLVANIA MIDDLE DISTRICT COMMONWEALTH OF PENNSYLVANIA : 84 MAP 2011 : : Appeal from the decision of the : Commonwealth Court (Opinion re Post- v. : Trial Motions of the Commonwealth and : Johnson & Johnson) dated 8/31/11 at No. : 212 MD 2004 TAP PHARMACEUTICAL PRODUCTS, : INC.; ABBOTT LABORATORIES; : ASTRAZENECA PLC; ASTRAZENECA, : HOLDINGS, INC.; ASTRAZENECA : PHARMACEUTICALS LP; : ASTRAZENECA LP; BAYER AG; BAYER : CORPORATION; SMITHKLINE : BEECHAM CORPORATION D/B/A : GLAXOSMITHKLINE; PFIZER, INC.; : PHARMACIA CORPORATION; : JOHNSON & JOHNSON; ALZA : CORPORATION; CENTROCOR, INC.; : ETHICON, INC.; JANSSEN : PHARMACEUTICAL PRODUCTS, L.P.; : MCNEIL-PPC, INC.; ORTHO BIOTECH, : INC.; ORTHO BIOTECH PRODUCTS; : L.P.; ORTHO-MCNEIL : PHARMACEUTICAL, INC.; AMGEN INC.; : IMMUNEX CORPORATION; BRISTOL- : MYERS SQUIBB COMPANY; BAXTER : INTERNATIONAL INC.; BAXTER : HEALTHCARE CORPORATION; : IMMUNO-U.S., INC.; AVENTIS : PHARMACEUTICALS, INC.; AVENTIS : BEHRING, L.L.C.; HOECHST MARION : ROUSSEL, INC., BOEHRINGER : INGELHEIM CORPORATION; : BOEHRINGER INGELHEIM : PHARMACEUTICALS, INC.; BEN VENUE : LABORATORIES; BEDFORD : LABORATORIES; ROXANE : LABORATORIES; SCHERING-PLOUGH : CORPORATION; WARRICK : PHARMACEUTICALS CORPORATION; : SCHERING SALES CORPORATION; : DEY, INC. : : DONNA A. BOSWELL, ESQ., ANN M. : VICKERY, ESQ., AND JOSEPH A. : YOUNG, ESQ., : Intervenors : : APPEAL OF: JOHNSON & JOHNSON, : ALZA CORPORATION, CENTOCOR, : INC., ETHICON, INC., JANSSEN : PHARMACEUTICAL PRODUCTS, L.P., : MCNEIL-PPC, INC., ORTHO BIOTECH, : INC., ORTHO BIOTECH PRODUCTS, : L.P., AND ORTHO-MCNEIL : PHARMACEUTICAL, INC. : (COLLECTIVELY, THE “JOHNSON & : JOHNSON DEFENDANTS”) : ORDER PER CURIAM DECIDED: June 16, 2014 AND NOW, this 16th day of June, 2014, the Order of the Commonwealth Court is VACATED, and the matter is remanded per the terms of Mr. Justice Baer’s responsive opinion in Commonwealth v. TAP Pharm. Prods., Inc., J-52B-2014, ___ A.3d ___ (Pa.
    [Show full text]
  • Lifescan Ethicon
    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • [J-52A-2014] in the SUPREME COURT of PENNSYLVANIA MIDDLE DISTRICT COMMONWEALTH of PENNSYLVANIA V. TAP PHARMACEUTICAL PRODUCTS, I
    [J-52A-2014] IN THE SUPREME COURT OF PENNSYLVANIA MIDDLE DISTRICT COMMONWEALTH OF PENNSYLVANIA : 84 MAP 2011 : : Appeal from the decision of the : Commonwealth Court (Opinion re Post- v. : Trial Motions of the Commonwealth and : Johnson & Johnson) dated 8/31/11 at No. : 212 MD 2004 TAP PHARMACEUTICAL PRODUCTS, : INC.; ABBOTT LABORATORIES; : ASTRAZENECA PLC; ASTRAZENECA, : HOLDINGS, INC.; ASTRAZENECA : PHARMACEUTICALS LP; : ASTRAZENECA LP; BAYER AG; BAYER : CORPORATION; SMITHKLINE : BEECHAM CORPORATION D/B/A : GLAXOSMITHKLINE; PFIZER, INC.; : PHARMACIA CORPORATION; : JOHNSON & JOHNSON; ALZA : CORPORATION; CENTROCOR, INC.; : ETHICON, INC.; JANSSEN : PHARMACEUTICAL PRODUCTS, L.P.; : MCNEIL-PPC, INC.; ORTHO BIOTECH, : INC.; ORTHO BIOTECH PRODUCTS; : L.P.; ORTHO-MCNEIL : PHARMACEUTICAL, INC.; AMGEN INC.; : IMMUNEX CORPORATION; BRISTOL- : MYERS SQUIBB COMPANY; BAXTER : INTERNATIONAL INC.; BAXTER : HEALTHCARE CORPORATION; : IMMUNO-U.S., INC.; AVENTIS : PHARMACEUTICALS, INC.; AVENTIS : BEHRING, L.L.C.; HOECHST MARION : ROUSSEL, INC., BOEHRINGER : INGELHEIM CORPORATION; : BOEHRINGER INGELHEIM : PHARMACEUTICALS, INC.; BEN VENUE : LABORATORIES; BEDFORD : LABORATORIES; ROXANE : LABORATORIES; SCHERING-PLOUGH : CORPORATION; WARRICK : PHARMACEUTICALS CORPORATION; : SCHERING SALES CORPORATION; : DEY, INC. : : DONNA A. BOSWELL, ESQ., ANN M. : VICKERY, ESQ., AND JOSEPH A. : YOUNG, ESQ., : Intervenors : : APPEAL OF: JOHNSON & JOHNSON, : ALZA CORPORATION, CENTOCOR, : INC., ETHICON, INC., JANSSEN : PHARMACEUTICAL PRODUCTS, L.P., : MCNEIL-PPC, INC., ORTHO BIOTECH, : INC., ORTHO BIOTECH PRODUCTS, : L.P., AND ORTHO-MCNEIL : PHARMACEUTICAL, INC. : (COLLECTIVELY, THE “JOHNSON & : JOHNSON DEFENDANTS”) : ORDER PER CURIAM DECIDED: June 16, 2014 AND NOW, this 16th day of June, 2014, the Order of the Commonwealth Court is VACATED, and the matter is remanded per the terms of Mr. Justice Baer’s responsive opinion in Commonwealth v. TAP Pharm. Prods., Inc., J-20B-2013, ___ A.3d ___ (Pa.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • James Burke: a Career in American Business (A)
    9-389-177 REV: OCTOBER 20, 2005 RICHARD S. TEDLOW WENDY K. SMITH James Burke: A Career in American Business (A) James Burke’s tenure as chief executive officer of Johnson & Johnson was drawing to a close in 1989. His career at the company began when he became brand manager for Band-Aids in 1953. At first he doubted whether Johnson & Johnson was the place for him. Soon, however, he committed himself wholeheartedly to the company and was quickly promoted to important positions within it. In 1976, he became chairman and chief executive officer. With Burke at the helm, the company grew smartly in terms of both sales and earnings. (See Exhibit 2.) One reason for this growth was an increase both in the number and the variety of products the company marketed, as well as in the vigor with which they were managed. Tylenol, for example, was still a specialty product in 1976—little known outside the hospital setting. By 1981, it had become the leading analgesic in the country by a wide margin. (See Exhibit 8.) Not all the company’s products fared so well, however. Some, such as CAT scanners, met with failure. James Burke’s Early Life James Edward Burke was born on February 28, 1925, in Rutland, Vermont. He spent his formative years in Slingerlands, New York, a small town near Albany. His father had served as an army officer before becoming an insurance and bond salesman. “My father had a wonderful view of the world,” Burke said. He was an optimist from the word go.
    [Show full text]
  • Open PDF File, 175.47 KB, for Top 100 Covered Recipients, Non Hospital
    Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events QUADRANT HEALTH BEVERLY MA Clinical 22D2063293 357395 Novartis CC0243 Other 61 $2,251,831.00 STRATEGIES INC Laboratory Pharmaceuticals 1 Total for Covered Recipient : QUADRANT HEALTH STRATEGIES INC $2,251,831.00 BOSTON BOSTON MA Clinical 22D0996308 241308 Celgene CC0109 Grants/ 2 $30,000.00 UNIVERSITY Laboratory Corporation Educational SCHOOL OF Gifts MEDICINE Csl Behring Llc CC0101 Education/ 2 $5,000.00 Training Depuy CC0135 CMEs, third- 2 $26,000.00 Orthopaedics, Inc., party Conferences, or Meetings Other 1 $7,500.00 Dr. Reddy's CC0592 Grants/ 2 $121,820.00 Laboratories, Inc Educational Gifts Janssen Biotech, CC0194 Grants/ 2 $105,000.00 Inc. Educational Gifts Other 1 $1,500.00 Janssen CC0535 CMEs, third- 2 $175,000.00 Pharmaceuticals, party Inc. Conferences, or Meetings Novo Nordisk Inc. CC0006 Grants/ 2 $136,436.00 Educational Gifts Smith & Nephew, CC0402 CMEs, third- 1 $1,000.00 Inc. party Conferences, or Meetings Stryker Corporation CC0290 CMEs, third- 1 $1,000.00 party Conferences, or Meetings Takeda CC0300 CMEs, third- 2 $60,218.00 Pharmaceuticals party Aug 1, 2016 1 8:44:29 AM Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events BOSTON BOSTON MA Clinical 22D0996308 241308 America, Inc CC0300 Conferences, or UNIVERSITY Laboratory Meetings SCHOOL OF Grants/ 3 $800,000.00 MEDICINE Educational Gifts Valeant CC0346 CMEs, third- 2 $5,000.00 Pharmaceuticals party North America Conferences, or Meetings W.L.
    [Show full text]
  • 130 Years of Medical Education at Johnson & Johnson
    BLAZING TRAILS: 130 Years of Medical Education at Johnson & Johnson MEDICAL INNOVATION MEDICAL EDUCATION INNOVATION 1887 Johnson & Johnson markets the 1888 first mass-produced sterile surgical dressings and sterile sutures. The company revolutionized the field of medicine, manufacturing the world’s first mass-produced antiseptic The Johnson brothers soon discovered medical supplies. that manufacturing sterile supplies was not enough—they needed to teach doctors how to use them. In 1888, the company published Modern Methods of Antiseptic Wound Treatment, a how-to guide on antiseptic surgery. The guide helped spread germ theory and antiseptic surgical methods. Just 13 years earlier, in 1875, surgeons had operated in street clothes and worked with unclean hands. 1895 Johnson & Johnson published Gauze Dressings in Surgery, a manual for the medical profession to introduce them to the new types of mass produced sterile dressings made by Johnson & Johnson, and explain their different uses in surgery, as well as the science behind their preparation. 1897 Johnson & Johnson scientific director Fred Kilmer published Asepsis Secundem Artem (“According to the Art of Asepsis”), a widely-read treatise on sterile wound care. A great deal of the scientific data in it was developed in the Johnson & Johnson Bacteriological Laboratory, which had been built by Kilmer to test and enhance improvements in sterilization techniques, based on the sterilization experiments of Robert Koch, one of the founders of microbiology. 1898 Johnson & Johnson begins publishing Red Cross Notes, a scientific journal for the medical profession, which contains articles related to new developments in surgery, wound treatment, asepsis and 1890s other topics. During World War I, Red Cross Notes featured articles designed In the 1800s, most babies were born to help inform and train surgeons on at home.
    [Show full text]
  • Weight Loss Surgery Care Guide
    0 Weight Loss Surgery Care Guide 0 1 Table of Contents Resources 3 Contact Information 3 Appointment Tracking 5 What to Expect on Surgery Day 7 Choosing Bariatric Surgery 10 Building Lifestyle Change 15 Nutrition 18 Meal Plan Progression 20 Liver Shrinking Diet 21 Enhanced Recovery After Surgery (ERAS) 22 Day of Surgery 22 After Surgery 23 Eating Progression 24 Stage 1 25 Stage 2 meal plan 27 Stage 3 meal plan 29 Stage 4 meal plan 31 Stage 5 meal plan 33 Stage 6 meal plan 35 Post-op week 6 and Beyond - Continued Guidance 37 Vitamins and Minerals 39 Protein Supplements 43 Portion Size Guidelines 46 Bariatric Meal Planning 47 Reading the Nutrition Facts Label 48 Identifying Hidden Sugars 49 Label Lingo 50 Food Quality 51 Mindful Eating 53 Hunger Fullness Scale 54 Making Smart Choices When Dining Out 55 Keeping a Food Journal 57 Optimizing Meal Duration 59 Keeping Liquids Separated from Meals 60 Nutrition Goal Worksheet 61 Setting Good Goals 63 Guidance Beyond Nutrition 66 Weight Loss Expectations 68 Medications 69 Physical Activity 71 Sleep 73 Common Concerns After Surgery 74 Dehydration 75 Dumping Syndrome 76 Constipation 77 Addressing Unhealthy Behaviors 79 Building Wellness through Self Awareness 80 Strategies for Lifelong Success 81 Learning More 82 2020 Bariatric Support Group Meetings 83 Updated November 11, 2020 2 Resources Contact Information For medical medical concerns, contact: Saint Joseph Weight Loss Center at Downtown Surgery Specialists 1960 Ogden Street, Suite 550 Denver, CO 80218 Phone 303-318-3240 Fax 303-812-6859 SaintJosephDenverWeightLoss.org Office hours: 8:00 A.M.
    [Show full text]